Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine used for treating diabetes mellitus

A diabetes and drug technology, applied in the field of medicine, can solve the problems of large fluctuations in blood sugar and urine sugar concentration, small reduction in blood sugar and urine sugar, and inability to take care of diabetic patients, so as to achieve blood sugar reduction, blood sugar and urine sugar reduction. Effect

Pending Publication Date: 2016-06-08
徐宝贞
View PDF6 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] (1) It has no obvious effect on lowering blood sugar;
[0011] (2) The degree of reduction in blood sugar and urine sugar is small, and it cannot take into account diabetic patients of different ages;
[0012] (3) After stopping the drug, the blood sugar and urine sugar concentration fluctuate greatly

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine used for treating diabetes mellitus
  • Medicine used for treating diabetes mellitus
  • Medicine used for treating diabetes mellitus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Embodiment 1 A kind of medicine for treating diabetes

[0038] The drug is marine algae glycoprotein;

[0039] Said marine algae glycoprotein, by weight content, comprises sugar 1%, protein 99%,

[0040] The molecular weight is 0.2kDa;

[0041] The marine algae are: cyanobacteria;

[0042] The sugar is a polysaccharide;

[0043] The polysaccharides include: glucose, mannose, rhamnose, galactose;

[0044] The protein includes: aspartic acid, glutamic acid, glycine, arginine, lysine, serine, threonine.

Embodiment 2

[0045] Embodiment 2 A kind of medicine for treating diabetes

[0046] The drug is marine algae glycoprotein;

[0047] Said marine algal glycoprotein, by weight content, comprises sugar 8%, protein 80%,

[0048] The molecular weight is 10kDa;

[0049] The marine algae is: green algae;

[0050] The sugar is a polysaccharide;

[0051] The polysaccharides include: glucose, mannose, rhamnose, galactose;

[0052] The protein includes: aspartic acid, glutamic acid, glycine, arginine, lysine, serine, threonine.

Embodiment 3

[0053] Embodiment 3 A kind of medicine for treating diabetes

[0054] The drug is marine algae glycoprotein;

[0055] Said marine algae glycoprotein, by weight content, comprises sugar 15%, protein 70%,

[0056] The molecular weight is 5kDa;

[0057] The marine algae are: cyanobacteria;

[0058] The sugar is a polysaccharide;

[0059] The polysaccharides include: glucose, mannose, rhamnose, galactose;

[0060] The protein includes: aspartic acid, glutamic acid, glycine, arginine, lysine, serine, threonine.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention provides medicine used for treating diabetes mellitus and complications thereof. The medicine is glycoprotein, or a mixture of polysaccharide and protein, or polypeptide or protein. The medicine has an obvious effect of reducing blood glucose of a rat diabetes model, and in the four weeks after the medicine is taken, the blood glucose of a rat is reduced from 27.06-27.19 mmol / L to 11.26-23.41 mmol / L. The medicine is used for treating diabetes mellitus continuously for four weeks, the result shows that a blood glucose value can be reduced obviously, the content of urine protein and the content of urea nitrogen in serum are reduced, the content of triglyceride in the serum is reduced, and the thymus indexes of the rat are increased. The medicine has the obvious effect of reducing the blood glucose and urine sugar of patients with the diabetes mellitus; meanwhile, the medicine has a function of adjusting hyperglycemia, hypertension, hyperlipidemia and high blood viscosity threatening the diabetes mellitus severely. The medicine has the advantages of being safe, efficient and free of side effects, and has the obvious effects of reducing the blood glucose, cholesterol and triglyceride.

Description

technical field [0001] The invention relates to a medicine for treating diabetes and belongs to the technical field of medicine. Background technique [0002] Diabetes mellitus is a chronic, metabolic disease characterized by hyperglycemia caused by defective insulin secretion or its biological action, or both. Diabetes is incurable and associated with several other diseases. It is the leading cause of blindness in people aged 25-74. 10% of diabetic patients are complicated with kidney disease. Diabetes is the most common cause of non-traumatic lower extremity amputation. There is a 30-fold increased risk of resection, a 2-4-fold increased risk of heart disease in diabetics, and a 5-fold increased risk of stroke. [0003] The cause of diabetes is unknown, but both genetic and environmental factors appear to play a role. There are two types of diabetes: insulin-dependent (type I) and non-insulin-dependent (type II). [0004] Type 1 diabetes is an autoimmune disease that of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/16A61P3/10A61K36/195A61K36/704A61K36/315A61K36/9064A61K31/7012A61K36/287A61K36/488A61K36/8984A61K36/8969A61K36/8967A61K36/8964A61K36/88A61K36/85A61K36/84A61K36/82A61K36/744A61K36/60A61K36/534A61K36/481A61K36/46A61K36/42A61K36/258A61K36/185A61K36/076
CPCA61K31/7012A61K35/748A61K36/02A61K36/03A61K36/04A61K36/05A61K36/076A61K36/185A61K36/195A61K36/258A61K36/287A61K36/315A61K36/42A61K36/46A61K36/481A61K36/488A61K36/534A61K36/60A61K36/704A61K36/744A61K36/82A61K36/84A61K36/85A61K36/88A61K36/8964A61K36/8967A61K36/8969A61K36/8984A61K36/9064A61K38/168A61K2300/00A61K31/404A61K36/28A61P3/10A61K36/48
Inventor 徐宝贞程潜程龙
Owner 徐宝贞
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com